Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more
Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released
On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients
read more
Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more Dr. Abbey Presented Preliminary Findings of a Diabetic Macular Edema Clinical Trial at the Retina World Congress
Texas Retina Associates’ Ashkan M. Abbey, MD served as an invited faculty member for the Retina World Congress held May 12-15, 2022, in Fort Lauderdale, Florida. This global physician meeting featured presentations
read more
Dr. Kothari and Dr. Abbey Earn “Top 10 Poster Award” at American Society of Retina Specialists 2021 Annual Scientific Meeting
A research poster by Texas Retina Associates physicians Nikisha Kothari, MD, and Ashkan M. Abbey, MD, was awarded “Top 10” honors at the American Society of Retina Specialists (ASRS) 2021 Annual Scientific
read more
New Clinical Trials Enrolling in Plano
At Texas Retina Associates, we remain committed to examining new options that are ethical, based on a solid science platform and provide minimal risks to our patients. Our Plano research team is
read more